Emerging therapies, AI, and patient-centered approaches are reshaping cardiovascular pharmacy.
Glenn Herrington, PharmD, FACC, FHFSA, BCCP, CPP, HFCert
Advertisement
Articles by Glenn Herrington, PharmD, FACC, FHFSA, BCCP, CPP, HFCert
Artificial intelligence is emerging as a vital tool for pharmacists in cardiovascular care—supporting clinical decisions, patient education, and adherence while maintaining guideline alignment.
Despite persistent gaps in cardiovascular risk management, pharmacists are proving essential in improving LDL control, guiding statin use, and supporting evidence-based care across clinical settings.
Pharmacists have become central to titration, access, patient education, and logistics as GLP-1 use grows and cardiometabolic management evolves.
Experts discuss guideline adoption, therapeutic advances, and team-based care.
Experts discuss practice expansion, guideline updates, and team-based care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
Why Some Patients Do Not Respond to GLP-1 Therapies
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5